Physician profile
Mark Williams
NPI 1770558702
$1,492.56
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.42 · 2020: $360 · 2021: $332 · 2022: $293 · 2023: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.78 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $649.19 | 2019-2023 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $219.01 | 2022-2023 | |
| Horizon Therapeutics Plc | $173.19 | 2020-2023 | Krystexxa |
| Medtronic, INC. | $162.22 | 2021 | |
| Organogenesis INC. | $108.07 | 2023 | Puraply |
| Otsuka America Pharmaceutical, INC. | $45.45 | 2021-2023 | Jynarque |
| Opko Pharmaceuticals, LLC | $39.14 | 2020 | |
| Mallinckrodt Hospital Products INC. | $23.51 | 2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.26 | 2023 | Jardiance |
| Akebia Therapeutics INC | $18.15 | 2021 | |
| Calliditas Therapeutics US INC. | $17.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.